Breastfeeding provides infant with optimal nutrients in the early stage of life, helping to establish a healthy gut microbiome, boost the immune system, and help with brain development. However, for some moms and babies, breastfeeding is hard to achieve.
HMOs (Human Milk Oligosaccharides) refer to carbohydrates or complex sugars found only in breast milk that have evolved over thousands of years. In fact, HMOs are the third most abundant solid component in breast milk, right after lipids and lactose. Scientific research has confirmed that each HMO has its own unique health benefits, so each HMO has its own structure and function as well as uses. Currently, there are more than 150 known HMOs in breast milk.
At Henglu, we have six main human milk oligosaccharides (HMOs) and are constantly developing new products. These product developments are backed by scientific research, and we actively support customers in developing innovative solutions to help formula-fed infants live a long and healthy life, which is part of Henglu’s commitment to population health.

Our clinical research evidence suggests that HMO:
Help to increase the relative abundance of beneficial bacteria while reducing the growth of potentially harmful bacteria; such as Clostridium difficile and E. coli (1)
May help gut bacterial composition recover after antibiotic use (1)
May help increase concentrations of beneficial bacterial metabolites, key nutrients for gut barrier and immune cells, while reducing harmful metabolites (2, 3, 4)
May support immune responses to rotavirus by modulating gut microbiota and immune cell populations (5, 6)

Clinical studies supplementing HMO, 2'FL + LNnT reported (7):
They are safe and well tolerated when supplemented with infant formula.
They help support the growth of good bacteria.
Compared to standard infant formula, significant 43% lower incidence of lower respiratory infections and 63% lower incidence of bronchitis in the first year of life
Compared to standard infant formula, significantly reduced use of antibiotics and fever medications in the first year of life.

The results of clinical studies using sugar-based HMOs, 2'FL and LNnT have shown(8):
2'FL and LNnT were safe and well tolerated in adults at doses up to 20 g/day.
2'FL and LNnT help support the growth of beneficial bacteria, especially Bifidobacteria.
Additionally, we are specifically investigating the effects of our HMO in obese children and participants with irritable bowel syndrome (IBS) in blinded and placebo-controlled clinical studies.

The next generation of HMO is part of Glycom's exciting innovation roadmap, with four new HMOs available for innovation trials in 2023 to further catalyze the already rapidly growing HMO market.
We currently offer HMOs in two HMO structural classes: 2'-fucosyllactose (2'FL), the most abundant fucosylated HMO in human milk, and lactate-N-neotetraose (LNnT), one of the most abundant neutral core HMOs in breast milk.